Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3016084 | 0.93 | LMNA (0.40) | LMNAMEN1KMT2AMAPK1CNR1 | |
| SCHEMBL3010728 | 0.93 | LMNA (0.40) | LMNAMEN1KMT2AMAPK1CNR1 | |
| SCHEMBL3011584 | 0.93 | LMNA (0.38) | LMNAMEN1KMT2AMAPK1CNR1 | |
| SCHEMBL3013526 | 0.91 | LMNA (0.47) | LMNAMEN1KMT2AMAPK1CNR1 | |
| SCHEMBL3013845 | 0.90 | LMNA (0.39) | THRBLMNAMEN1KMT2AMAPK1 | |
| SCHEMBL3002366 | 0.90 | LMNA (0.39) | LMNAMEN1KMT2AMAPK1CNR1 | |
| SCHEMBL3006978 | 0.90 | LMNA (0.41) | LMNAMEN1KMT2ACNR2TP53 | |
| SCHEMBL3018440 | 0.90 | TP53 (0.43) | LMNAMEN1KMT2AMAPK1TP53 | |
| SCHEMBL3018624 | 0.89 | CACNA1G (0.38) | LMNAMEN1KMT2AMAPK1CNR1 | |
| SCHEMBL3014957 | 0.88 | LMNA (0.39) | LMNAMEN1KMT2AMAPK1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188272-B1 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2016-02-24 | — | — | EP | disclosed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20110082151-A1 | SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| EP-2188272-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV Remynd (BE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009019295-A2 | PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082151-A1 | SULFONYLUREA MODULATORS OF ENDOTHELIN RECEPTOR | EDNRA, EDNRB, GLP1R | THRB 748/4885LMNA 2311/4885MEN1 2742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.